Allena Pharmaceuticals, Inc. Financing cash flow

Financing cash flow of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Financing cash flow growth rates and interactive chart.


Highlights and Quick Summary

  • Financing cash flow for the quarter ending March 31, 2022 was $-1.06 Million (a -144.09% decrease compared to previous quarter)
  • Year-over-year quarterly Financing cash flow decreased by -159.8%
  • Annual Financing cash flow for 2021 was $41.3 Million (a 22.07% increase from previous year)
  • Annual Financing cash flow for 2020 was $33.8 Million (a 179.14% increase from previous year)
  • Annual Financing cash flow for 2019 was $12.1 Million (a -1846.11% decrease from previous year)
  • Twelve month Financing cash flow ending March 31, 2022 was $28.5 Million (a -30.9% decrease compared to previous quarter)
  • Twelve month trailing Financing cash flow decreased by -19.78% year-over-year
Trailing Financing cash flow for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$28.5 Million $41.3 Million $52.3 Million $35.6 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Financing cash flow of Allena Pharmaceuticals, Inc.

Most recent Financing cash flowof ALNA including historical data for past 10 years.

Interactive Chart of Financing cash flow of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Financing cash flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-1.06
2021 $2.4 $25.43 $1.77 $11.7 $41.29
2020 $13.37 $8.73 $12.73 $-1.0 $33.83
2019 $2.51 $-0.01 $9.61 $0.01 $12.12
2018 $-0.04 $-0.04 $0.58 $-1.19 $-0.69
2017 $67.46 $-0.57 $0.0 $0.0 $66.89
2016 $2.5 $0.9 $3.4
2015 $55.29 $55.3

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.